Federal cannabis rescheduling just made history. But if you think state borders are about to open for cannabis products, one industry leader has a sharp reality check for you. Vince Ning, CEO and co-founder of Nabis, America’s largest cannabis wholesale platform, says the road to interstate commerce is far more complicated than most operators expect, and real answers may only arrive after years of court battles.
What Rescheduling Actually Changed, and What It Did Not
On April 23, 2026, the U.S. Department of Justice made the most consequential move in federal cannabis history in more than 50 years. Acting Attorney General Todd Blanche signed a final order immediately placing state-licensed medical marijuana and FDA-approved cannabis products in Schedule III of the Controlled Substances Act.
But the celebration came with a massive asterisk.
Adult-use recreational marijuana remains firmly in Schedule I. Interstate commerce is still restricted under federal law. The broader classification of all cannabis as Schedule III now depends on a new DEA administrative hearing set to begin on June 29, 2026.
The single biggest immediate financial win is Section 280E tax relief. Before this order, cannabis businesses could not deduct ordinary expenses like rent, payroll, or marketing, resulting in effective federal tax rates of 70 to 90 percent compared to the standard 21 percent corporate rate. For qualifying medical operators, that crushing tax burden is now lifted as of January 1, 2026.
Still, as Vince Ning makes clear, a lower tax bill is not the same as an open national market. Rescheduling does not automatically clear the way for cannabis products to flow freely between states, whether medical or adult-use.
The Three-Lane Market Nobody Is Talking About
According to Ning, the industry needs to stop treating cannabis as one unified market heading toward a single national outcome. The market, he says, will divide into three distinct operating lanes going forward.
- Intoxicating hemp products, regulated under a shifting and increasingly tightened federal hemp framework
- State-licensed medical marijuana, now partially covered under Schedule III with a new DEA registration pathway
- Adult-use recreational cannabis, still sitting in Schedule I with no federal recognition
Each lane runs under a different legal framework. Rescheduling does not blend them into one national market.
The clearest path toward any form of interstate commerce runs through the medical lane. Companies that obtain DEA registration may be able to transact with other DEA-licensed parties. But Ning is quick to warn the road will not be smooth. He expects litigation from companies that read the new rules one way, get rejected, and challenge those decisions in court.
“I think a lot of it is still left up to interpretation,” Ning told MJBizDaily.
States like California, Oregon, and Washington have already passed laws allowing licensed cannabis businesses to transport THC products across state lines, but only if the federal government legalizes marijuana or its interstate trade. Those state-level trigger clauses have been sitting dormant, waiting for exactly this kind of federal movement.
Ning warns that opening those floodgates too fast carries its own risks. States with smaller or already oversupplied markets fear that California products flooding in would immediately crash local prices. In response, he believes many states would quickly impose import and export tariffs and interstate commerce taxes to protect their domestic cannabis industries.
Why the DEA Cannot Simply Fix This
Here is where the optimism inside the cannabis industry runs straight into a wall of bureaucratic reality.
The DEA is a law enforcement agency. It was built to fight drug trafficking, not to regulate commercial markets the way the Alcohol and Tobacco Tax and Trade Bureau does for alcohol. Ning points out that the DEA is simply not designed to function as a commercial market regulator for a multi-billion-dollar industry.
The DEA operates on an annual budget of roughly $3.1 billion. That is a fraction of what other major federal agencies receive, and resource constraints will directly shape how quickly and how thoroughly the agency can issue guidance, process registrations, and build a viable framework for the industry.
That concern is already backed by evidence. Congressional researchers have questioned whether the DEA has the capacity to enforce new federal hemp product restrictions arriving in November 2026. Calling its enforcement mechanisms “unclear” is a polite way of saying the infrastructure is not yet in place.
Medical operators had a 60-day window starting April 28, 2026, to file for expedited DEA registration. Companies that registered within that window can operate under their state licenses while the DEA reviews their applications, which must be processed within six months. That window officially closed on June 22, 2026. Companies that missed it may face a slower and less protected path to federal legitimacy.
How Cannabis Operators Should Position Themselves Now
Despite the legal fog, Nabis itself is not waiting on the sidelines. The company powers over $1 billion annually in licensed cannabis commerce across the United States and has been building aggressively.
In January 2026, Nabis acquired select assets of Humble Cannabis Solutions, expanding its footprint across Northern California, the Central Coast, and Southern California. Then in May 2026, the company entered New Jersey by acquiring Hudson Distribution Services’ cannabis distribution license, positioning itself in the tri-state area ahead of what many in the industry expect to be a future interstate commerce framework.
For operators watching these moves, Ning’s message to the broader industry is direct. Federal reform is a strategic boost for long-term growth, not a quick rescue from the industry’s current financial pressures.
| Action for Operators | Why It Matters Now |
|---|---|
| Apply for DEA registration | Opens door to potential interstate commerce and first-mover protections |
| Rework federal tax strategy | 280E relief is live for qualifying medical operators |
| Separate medical and adult-use accounting | IRS guidance is coming; clean books will matter |
| Monitor the June 29 DEA hearing | This will determine whether adult-use cannabis enters Schedule III |
| Watch for state tariff legislation | States may restrict cross-border trade to protect local markets |
The broader rescheduling hearing beginning June 29, 2026, is the single most important regulatory event to watch. If the process moves on the DOJ’s timeline, a final rule could arrive as soon as late 2026. But litigation from anti-rescheduling groups, including organizations that have already retained prominent legal counsel, could push that timeline back considerably.
The question is not whether rescheduling will face legal challenges. It is which path produces a rule that survives them.
Reform signals are real. The momentum in Washington is building. But as Vince Ning sees it, the cannabis industry just earned a significant federal win, not a finish line. Real interstate commerce, if and when it arrives, will be built through years of legal battles, registration frameworks, and a market learning to operate in three separate lanes at once. For an industry that has fought this hard and waited this long, patience is not just a virtue right now. It is a survival strategy. What do you think? Will true interstate cannabis commerce become a reality within the next five years? Drop your thoughts in the comments below.